What Elevat Treats: Main Uses and Benefits

Elevat (Dronabinol) is applied in specialized clinical settings to manage severe, disruptive symptomatic patterns, with anti-sickness and appetite-stimulating effects.

This medication is commonly used to help with two primary indications: nausea and vomiting associated with cancer chemotherapy that is difficult to manage or refractory to initial antiemetic treatments, and anorexia linked to significant weight loss in patients with Acquired Immunodeficiency Syndrome (AIDS).

The core benefit is to provide supportive relief during difficult episodes, addressing groups of symptoms that may become intense or disruptive. The medication is relevant for easing symptoms that create noticeable physiological strain, particularly when patients experience acute distress. The primary function is to support nutritional status and helps ease severe emesis in highly specific, challenging clinical situations.

Quick Fact: Relief for Severe Sickness and Wasting

• Elevat is considered relevant when supportive symptom management is appropriate for severe, difficult-to-control emesis.
• It assists with maintaining functional stability by addressing persistent appetite loss and physical wasting.
• It supports patients during episodes of heightened discomfort by helping ease the overall symptom load.

Regulatory References

1. NIH MedlinePlus overview

Eligibility Scope

Populations for whom use is allowed (as stated in label):

• Adults (18 years and older) approved for treating Chemotherapy-Induced Nausea and Vomiting (CINV) when conventional antiemetics have failed.
• Adults approved for managing Anorexia associated with weight loss in patients with AIDS.

Populations for whom use is contraindicated:

• Patients with a history of hypersensitivity reaction to Dronabinol or any component of the specific Elevat formulation.
• Patients with a known allergy to sesame oil (applies specifically to the oral capsule formulation).
• Patients with a known allergy to alcohol or those recently treated with Disulfiram or Metronidazole (applies specifically to the oral solution formulation).

Age-related eligibility rules:

• Pediatric Patients (under 18 years of age): Safety and effectiveness have not been established, and use is generally not recommended.
• Older Adults (Geriatric): Conditional use is warranted; a lower starting dose should be considered due to increased sensitivity to neuropsychiatric and hypotensive effects.

Pregnancy and lactation eligibility status:

• Pregnancy: Use is not recommended due to potential for fetal harm.
• Lactation: Use is not recommended; women should not breastfeed during treatment and for a specified time afterward.

Eligibility-related restrictions:

• Patients with a history of psychiatric disorders (e.g., mania, depression, schizophrenia) must be carefully monitored, or use must be avoided.
• Patients with cardiac disorders, a history of seizures, or substance abuse or dependence must only use the medicine under restrictive, monitored conditions.

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents):

• Contraindicated (Absolute prohibition due to hypersensitivity/allergy).
• Not Recommended (Prohibition or strong caution in reproductive or pediatric groups).
• Use with Caution/Restricted Use (Conditional allowance in older adults and patients with specific comorbidities).

Connection to the overall eligibility profile: Regulatory documents strictly define who can and cannot use Elevat by establishing two primary contraindications (hypersensitivity and excipient allergy) and restricting use based on age and physiological status. These restrictions mandate caution or prohibition in pediatric, geriatric, and reproductive populations, and they impose strict conditional use for patients with a documented history of certain psychiatric, cardiac, or seizure disorders.

Elevat (Dronabinol) has officially documented interaction patterns primarily involving hepatic metabolism and effects on the central nervous system.

Pharmacokinetic and Pharmacodynamic Interactions

Formulations and Timing Restrictions

The oral solution formulation of Elevat contains alcohol (ethanol) and carries specific restrictions related to the risk of a disulfiram-like reaction. Disulfiram and Metronidazole are contraindicated with the oral solution and require a strict, mandatory separation period of at least 14 days before starting Dronabinol and 7 days after stopping. Dosing of Dronabinol relative to food intake must be kept consistent due to food's substantial effect on systemic exposure. Regulatory guidance notes that geriatric patients and those with specific genetic polymorphisms (CYP2C9 poor metabolizers) may experience increased sensitivity or exposure to Dronabinol.

The mechanism of action of Dronabinol (Elevat) is anchored in the partial agonism of the Cannabinoid Receptor Type 1 (CB1), found predominantly within the Central Nervous System (CNS). This molecular interaction initiates an inhibitory cascade within targeted neurons via Gi/Go protein coupling, leading to a decrease in the intracellular secondary messenger cyclic AMP (cAMP) and a subsequent modulation of neurotransmitter release. Functionally, this CB1 activation is concentrated in the brainstem's emetic control centers and the hypothalamic nuclei that regulate energy balance. This targeted modulation initiates an inhibitory signal within the emetic pathway and alters the balance of orexigenic and anorexigenic signaling in the hypothalamus. The receptor system is subject to desensitization and down-regulation following continuous exposure, a dynamic constraint that illustrates the inherent limitations and variability of CB1-mediated physiological response.

The use of Elevat (capsule form) follows specific parameters detailing the route, frequency, and administration conditions as prescribed by a healthcare provider. The dose is highly individualized and must be followed exactly as advised by the prescribing doctor.

Administration Guidelines

Procedural Rules

Missed Dose: If a dose of the capsule is missed, the standard procedure is to take the next scheduled dose at the usual time. This ensures a return to the regular daily pattern, and patients should not take a double dose to compensate for the missed one.

Special Conditions:

• Duration of Use: The medicine must be taken only for the duration advised by your doctor, regardless of how the patient feels.
• Pediatric Use (Topical Cream): Specific rules apply to other forms of the drug; for instance, the topical cream form requires consulting a doctor for use in children under 12 years of age.

The overall use protocol requires strict patient adherence to the dose, frequency, and duration set by the prescriber. It is emphasized that the patient should not independently alter the dose or discontinue the treatment, reinforcing a medically supervised protocol.

Recent Clinical Evidence

Overview of Key Research Findings

Research involving the drug focused on populations with moderate to severe rheumatoid arthritis (RA). Studies have primarily investigated its use in participants who had an inadequate response to other disease-modifying antirheumatic drugs (DMARDs), such as methotrexate.

A key meta-analysis examined whether participants reported changes in pain levels. Some studies in this analysis documented data points measured during the initial weeks of treatment. Studies investigated whether changes in joint inflammation were detected over a six-month period. Research assessments also included comparisons that involved older treatments.

Combination Therapy Studies

Research has explored the drug's profile when studied alongside methotrexate. Most studies involved participants taking the drug in this combination. Findings from these studies reported on participant outcomes when the two treatments were used together.

Research studies specifically evaluated the lower dose in participants with mild symptoms. Researchers also examined safety data reported by study participants.

Research in Other Conditions

Psoriatic Arthritis (PsA)

Research examined the drug in the context of psoriatic arthritis, with data points collected for both peripheral and axial joint disease. This condition was evaluated in clinical trials focusing on joints, skin, and quality of life measures.

Axial Spondyloarthritis (AS)

Studies investigated the drug's use in axial spondyloarthritis. This included participants with radiographic (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). This approach was explored for cases considered difficult to treat in the studies. These trials collected data related to reported symptoms and functional measures across the study period.

Key Studies & References

1. UCB announces U.S. FDA approvals for BIMZELX® (bimekizumab-bkzx) for the treatment of psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis (FDA Regulatory Document referencing Phase 3 studies)

Common questions about Elevat (FAQ)

Q: What is Elevat used for, besides the main condition?

Official regulatory documents indicate that Dronabinol (Elevat) is approved to treat severe feelings of sickness and vomiting associated with chemotherapy in patients who have not responded to other treatments. It is also approved for managing loss of appetite and associated weight loss in adult patients with AIDS.

Q: Does Elevat help immediately, or does it take time to work?

Studies indicate that the onset of action after taking Elevat is relatively quick, generally within 30 minutes to one hour. The peak psychoactive effect usually occurs a few hours after administration. However, the effect of stimulating appetite may be sustained for 24 hours or longer.

Q: Can I take Elevat with pain relievers like Advil or Tylenol?

Elevat is processed in the body by specific liver enzymes known as CYP2C9 and CYP3A4. Some common pain relievers can either speed up or slow down the action of these same enzymes. Taking Elevat alongside such medications may change how much of the drug stays in the bloodstream, and official guidance requires that your healthcare provider be informed about all concomitant medications.

Q: Do many people experience side effects with Elevat?

Yes, regulatory documents report common adverse reactions, meaning they occurred in 3% to 10% of participants in clinical trials. These frequently reported effects often involve the nervous system, such as dizziness, somnolence (sleepiness), euphoria, and changes in thinking.

Q: Are there any specific foods to avoid when using Elevat?

While no specific foods are prohibited, regulatory guidance notes that taking the medication with a high-fat, high-calorie meal can significantly affect how the drug is absorbed. This could delay the onset of its effects and increase the total amount of the drug in the system.

Q: Does Elevat affect my ability to drive or operate machinery?

Yes, official safety information warns that Elevat can cause mental and physical impairment, including dizziness, confusion, and somnolence (sleepiness). The labeling advises patients against operating a motor vehicle or complex machinery until they understand how the drug affects them personally.

Q: Is it true that Elevat can cause weight gain or loss?

Elevat is officially indicated for the management of anorexia associated with weight loss by stimulating the appetite in certain patient populations. However, official safety reports also list anorexia (loss of appetite) as a less common adverse reaction.

Q: Can Elevat be taken while using herbal supplements?

Many herbal or natural supplements are known to influence the same liver enzymes (CYP enzymes) that process Elevat. Because of this, combining them could change the amount of the drug in the bloodstream, potentially leading to increased side effects.

Q: Do the side effects of Elevat go away over time?

Regulatory documents indicate that the body can develop tolerance to some of the central nervous system (CNS) adverse effects with continued use. For example, some common CNS side effects may resolve on their own within one to three days.

Q: Is it normal to feel a change in energy levels when starting Elevat?

Official reports indicate that both asthenia (physical weakness) and fatigue are possible adverse reactions. Additionally, the common central nervous system effects, such as somnolence (sleepiness) and euphoria, are changes that can affect one's overall feeling of energy.

Q: How does Elevat affect sleep patterns?

Official patient information states that somnolence (sleepiness) is a common adverse reaction associated with this medication. Difficulty falling or staying asleep (insomnia) and nightmares are also listed as less common adverse reactions.

Q: Does Elevat interact with over-the-counter cold medicines?

Many over-the-counter cold medications contain ingredients, such as certain antihistamines, that can act as Central Nervous System (CNS) depressants. Combining these with Elevat may lead to increased side effects like dizziness, somnolence, and confusion due to an additive effect.

Q: What happens if I stop taking Elevat suddenly?

Official documents state that if Elevat is stopped suddenly, particularly after taking high doses, patients may experience an abstinence syndrome (withdrawal). Potential symptoms include irritability, difficulty sleeping, restlessness, and physical symptoms like sweating and a runny nose.

Q: How long does the effect of Elevat typically last?

Official studies note that the psychoactive effects of the drug typically last approximately 4 to 6 hours. However, the appetite-stimulating effects of the drug may continue for 24 hours or longer after a single administration.

Q: How long have studies on Elevat been conducted?

The active ingredient in Elevat, Dronabinol, has been the subject of research for several decades, having received its initial FDA approval in the mid-1980s. The current labeling reflects research and data collected continuously since that time.

Q: Does Elevat interact with birth control pills?

Official product information states that Elevat is highly bound to proteins in the blood. Because of this, it has the potential to displace other highly protein-bound medications, which may change their concentration in the bloodstream.

Q: Can men and women use Elevat the same way?

The general administration instructions for Elevat are the same for all adults. However, use is strongly cautioned or contraindicated in women who are pregnant or breastfeeding due to the potential for harm to the fetus or infant.

Q: What should I do if I feel drowsy after taking Elevat?

If you experience drowsiness, official instructions advise against driving or operating complex machinery. Should this symptom feel severe, be disruptive, or not go away, the regulatory guidance suggests consulting with your prescribing healthcare provider about a potential dosage adjustment.

Q: Are there official reports about long-term use of Elevat?

Official studies tracking the drug's use in patients with AIDS found that the appetite-stimulant effect was sustained for up to five months in clinical trials. Furthermore, official documentation notes that tolerance to some of the central nervous system effects may develop with chronic exposure.

Q: Can people with liver or kidney issues take Elevat?

Regulatory documents note that Elevat undergoes extensive processing in the liver and is eliminated from the body through both feces and urine. Because of this, patients with pre-existing liver or kidney conditions may experience altered metabolism and elimination of the drug.

Q: What makes Elevat a prescription-only drug?

Elevat is classified as a Schedule III controlled substance under federal law. This classification is assigned because the drug has an accepted medical use but also possesses a documented potential for abuse and dependence, which requires strict regulation and medical supervision.

Q: Are there any travel restrictions while taking Elevat?

Since Elevat is a Schedule III controlled substance, carrying it across state lines or international borders may be subject to specific legal restrictions and documentation requirements. It is necessary to confirm local laws and carry official prescription documentation when traveling with the medication.

Q: Is Elevat chemically similar to any older drugs?

Official patient information identifies the active ingredient, Dronabinol, as a chemically synthesized form of tetrahydrocannabinol (THC). THC is the main psychoactive component naturally found in the cannabis plant.

Storage and Stability Requirements

Official storage conditions for Elevat (Dronabinol) are dependent on the dosage form and are designed to maintain product stability:

• Oral Capsules: Must be stored at controlled room temperature, specifically 20 C to 25 C (68 F to 77 F), in a well-controlled container.
• Oral Solution: Requires refrigerated storage at 2 C to 8 C (36 F to 46 F). The solution must be stored upright, kept tightly closed, and must not be frozen.

All forms must be protected from light. The oral solution has an in-use stability limit and must be discarded 42 days after first opening.

Disposal and Safety

Elevat must be stored out of the sight and reach of children. Unused or expired medication must be disposed of through an authorized drug take-back program or in accordance with local regulations for controlled substance waste. It must not be flushed down the toilet or placed in household trash.